A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302)

PHASE3CompletedINTERVENTIONAL
Enrollment

801

Participants

Timeline

Start Date

July 11, 2017

Primary Completion Date

July 24, 2018

Study Completion Date

July 24, 2018

Conditions
Acne Vulgaris
Interventions
DRUG

IDP-123 Lotion

Tazarotene 0.045% Lotion

DRUG

IDP-123 Vehicle Lotion

Vehicle Lotion

Trial Locations (45)

10155

Valeant Site 10, New York

11790

Valeant Site 33, Stony Brook

14623

Valeant Site 43, Rochester

19008

Valeant Site 28, Broomall

20850

Valeant Site 19, Rockville

22911

Valeant Site 21, Charlottesville

30078

Valeant Site 44, Snellville

33144

Valeant Site 02, Miami

33406

Valeant Site 26, West Palm Beach

33437

Valeant Site 05, Boynton Beach

33458

Valeant Site 38, Jupiter

33761

Valeant Site 29, Clearwater

36608

Valeant Site 41, Mobile

37130

Valeant Site 14, Murfreesboro

37922

Valeant Site 18, Knoxville

40241

Valeant Site 32, Louisville

48038

Valeant Site 37, Clinton Township

48059

Valeant Site 20, Fort Gratiot

48346

Valeant Site 30, Clarkston

48706

Valeant Site 08, Bay City

55432

Valeant Site 24, Fridley

72758

Valeant Site 22, Rogers

73112

Valeant Site 11, Oklahoma City

75234

Valeant Site 07, Dallas

77479

Valeant Site 39, Sugar Land

77845

Valeant Site 23, College Station

78218

Valeant Site 04, San Antonio

78660

Valeant Site 27, Pflugerville

80220

Valeant Site 25, Denver

84041

Valeant Site 09, Layton

84088

Valeant Site 15, West Jordan

87106

Valeant Site 42, Albuquerque

92008

Valeant Site 34, Carlsbad

92123

Valeant Site 06, San Diego

Valeant Site 13, San Diego

Valeant Site 31, San Diego

92701

Valeant Site 36, Santa Ana

94538

Valeant Site 12, Fremont

99362

Valeant Site 35, Walla Walla

07960

Valeant Site 03, Morristown

02886

Valeant Site 16, Warwick

V3VOC6

Valeant Site 01, Surrey

R3M3Z4

Valeant Site 45, Winnipeg

N8W5L7

Valeant Site 40, Windsor

J7Z3B8

Valeant Site 17, Saint-Jérôme

All Listed Sponsors
lead

Bausch Health Americas, Inc.

INDUSTRY

NCT03168334 - A Phase 3, Vehicle-controlled Efficacy and Safety Study of IDP-123 Lotion in the Treatment of Acne Vulgaris (302) | Biotech Hunter | Biotech Hunter